In This Article:
A look at the shareholders of Evaxion Biotech A/S (NASDAQ:EVAX) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. I quite like to see at least a little bit of insider ownership. As Charlie Munger said 'Show me the incentive and I will show you the outcome.
Evaxion Biotech is not a large company by global standards. It has a market capitalization of US$134m, which means it wouldn't have the attention of many institutional investors. Our analysis of the ownership of the company, below, shows that institutions don't own shares in the company. Let's delve deeper into each type of owner, to discover more about Evaxion Biotech.
View our latest analysis for Evaxion Biotech
What Does The Lack Of Institutional Ownership Tell Us About Evaxion Biotech?
We don't tend to see institutional investors holding stock of companies that are very risky, thinly traded, or very small. Though we do sometimes see large companies without institutions on the register, it's not particularly common.
There are multiple explanations for why institutions don't own a stock. The most common is that the company is too small relative to funds under management, so the institution does not bother to look closely at the company. Alternatively, there might be something about the company that has kept institutional investors away. Evaxion Biotech's earnings and revenue track record (below) may not be compelling to institutional investors -- or they simply might not have looked at the business closely.
We note that hedge funds don't have a meaningful investment in Evaxion Biotech. The company's largest shareholder is Niels Møller, with ownership of 22%. Andreas Mattsson is the second largest shareholder owning 22% of common stock, and Guillermo Zuloaga holds about 4.3% of the company stock. Andreas Mattsson, who is the second-largest shareholder, also happens to hold the title of Top Key Executive. In addition, we found that Lars Wegner, the CEO has 0.9% of the shares allocated to their name.
Our research also brought to light the fact that roughly 51% of the company is controlled by the top 5 shareholders suggesting that these owners wield significant influence on the business.
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.